16CI 05/13

PATENT OKL010-107/00727A Customer No.24,118

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APPLICANT: BROYLES ET AL.)

OCT 3 1 2002

SERIAL NO.:

10/003,669

TECH CENTER 1600/2900

FILED:

NOVEMBER 1, 2001

FOR:

GENE REGULATION

THERAPY INVOLVING

FERRITIN

GROUP ART UNIT:

EXAMINER:

UNKNOWN

INFORMATION DISCLOSURE STATEMENT

Assistant Director of Patents Washington, D. C. 20231

Sir:

In compliance with the duty of disclosure set out in 37 C.F.R. §1.56, attached hereto is Form PTO-1449 containing a list of patents and/or publications for Applicant's Information Disclosure Statement.

Each listed patent and/or publication is considered relevant to the subject application in that they individually and collectively disclose a sampling of what has been previously employed in the arts related to gene regulation therapy involving ferritin.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Director of Patents, Washington, D.C. 20231, on March 21, 2002

.

Applicant respectfully requests consideration of each of the listed patents and/or publications during examination of the present application.

Identification of Person(s) Making This INFORMATION DISCLOSURE STATEMENT

The person making this statement is:

(a)	the inventor(s)	who signs	below
-----	-----------------	-----------	-------

SIGNATURE OF INVENTOR

Name of Inventor Signing

- (b) X the attorney who signs below on the basis of:
 - ____ the information supplied by the inventor(s)
 - __ which has been reviewed by the attorney
 - which has not been reviewed by the attorney
 - X the information in the attorney's file

Date: March 21, 200

Mark O. Kachigian, Registration No. 32,840

Head, Johnson & Kachigian

228 West 17th Place

Tulsa, Oklahoma 74119

(918) 587-2000

Attorneys for Applicant